MediWound (NASDAQ:MDWD) Director Purchases $49,907.07 in Stock

MediWound Ltd. (NASDAQ:MDWD) Director David Morton Fox acquired 3,537 shares of the firm’s stock in a transaction dated Monday, June 1st. The shares were purchased at an average cost of $14.11 per share, for a total transaction of $49,907.07. Following the completion of the acquisition, the director directly owned 22,283 shares in the company, valued at approximately $314,413.13. This represents a 18.87% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

MediWound Stock Performance

NASDAQ MDWD opened at $13.82 on Tuesday. The stock has a 50 day moving average price of $16.56 and a 200-day moving average price of $17.40. MediWound Ltd. has a one year low of $13.61 and a one year high of $22.50. The company has a market capitalization of $177.59 million, a P/E ratio of -6.12 and a beta of 0.16.

MediWound (NASDAQ:MDWD) last announced its quarterly earnings results on Wednesday, May 27th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.65) by $0.42. The company had revenue of $1.48 million for the quarter, compared to analysts’ expectations of $3.37 million. MediWound had a negative net margin of 180.30% and a negative return on equity of 67.22%. During the same quarter in the previous year, the business posted ($0.07) earnings per share. As a group, equities analysts predict that MediWound Ltd. will post -2.49 EPS for the current fiscal year.

Hedge Funds Weigh In On MediWound

Hedge funds have recently bought and sold shares of the business. Quarry LP bought a new stake in shares of MediWound during the fourth quarter worth $26,000. BNP Paribas Financial Markets grew its holdings in shares of MediWound by 90.4% in the third quarter. BNP Paribas Financial Markets now owns 1,523 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 723 shares during the last quarter. Russell Investments Group Ltd. increased its stake in MediWound by 69.1% in the 2nd quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 649 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in MediWound by 22.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock worth $85,000 after buying an additional 999 shares during the period. Finally, MetLife Investment Management LLC bought a new stake in MediWound during the 4th quarter valued at about $109,000. Institutional investors own 46.83% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently issued reports on the stock. HC Wainwright restated a “buy” rating and set a $36.00 target price on shares of MediWound in a research report on Thursday, May 28th. Wall Street Zen upgraded MediWound from a “strong sell” rating to a “sell” rating in a research report on Saturday. Oppenheimer reissued an “outperform” rating and set a $32.00 price objective (down from $33.00) on shares of MediWound in a research note on Wednesday, May 27th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of MediWound in a research report on Tuesday, April 21st. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $34.00.

MediWound Company Profile

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.